Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma

Table 6 Characteristics of the study population according to use of ribavirin

	Number (%)
Characteristic	RBV-containing DAA regimens (n = 68)	Non-RBV containing DAA regimens (n = 38)	P value
Age ≥ 60 yr	38 (58)	26 (70)	0.2
Male	51 (75)	24 (63)	0.3
Female	17 (25)	14 (37)
White	37 (54)	19 (50)	0.8
Black	15 (22)	7 (18)
Hispanic	13 (19)	10 (26)
Asian	3 (4)	2 (5)
Diabetes Mellitus	45 (66)	28 (74)	0.5
CKD	22 (32)	21 (55)	0.02
eGFR < 30 mL/min/1.73 m2	1 (2)	8 (21)	0.001
Cirrhosis	4 (8)	5 (16)	0.3
mean (± SD) creatinine level, mg/dL	1.2 ± 1.0	1.9 ± 1.8	0.02
mean (± SD) hemoglobin level, g/dL	14.0 ± 1.7	12.0 ± 2.0	0.0001
mean (± SD) MELD-Na score	11 ± 4	13 ± 6	0.01
SVR12	65 (95.5)	35 (92.1)	0.7

RBV: Ribavirin; CKD: Chronic kidney disease; DAA: Direct-acting antiviral; SVR: Sustained virologic response.